NCT07744126 — Head and Neck Squamous Cell Carcinoma trial site landscape

Public-registry site landscape for NCT07744126, “A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma”, a Head and Neck Squamous Cell Carcinoma study sponsored by AbbVie. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07744126 (registry record)
Study title	A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Official title	A Phase 2 Open-Label Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Pembrolizumab as First-Line Treatment in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sponsor	AbbVie
Condition(s)	Head and Neck Squamous Cell Carcinoma
Phase	PHASE2
Listed sites	20
Site countries	United States, China, Japan, Portugal, Spain

Patient-friendly overview of this study: eichor.com/study/NCT07744126.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07744126 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →